About Max
This author has not written his bio yet.
But we are proud to say that Max contributed 756 entries already.
Entries by Max
Newsletter 19/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! After two weeks of indigestion from new clinical trials and preclinical studies due to the international conferences AACR 2025 and AUA 2025, we’re back to a more modest amount of information—but no less interesting because of it! Stay strong […]
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Another Phase 1/2 Trial With SX-682, Combined With Docetaxel This Time June 26, 2026
- Phase 1 Trial for a New PSMA Radioligand 177Lu‑PSMA‑VG01 June 25, 2026
- Darolutamide Versus Abiraterone-Based Triplets in mHSPC: Real-World Signals from the ARON-3 Study June 25, 2026
- A New Clue for Prostate Cancer Survival June 23, 2026
